Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Galecto Inc. (NASDAQ:GLTO) stock tripled on Monday, with a session volume of 23.26 million, compared to the average volume of 2.41 million, as per data from Benzinga Pro.Galecto acquired Damora Therapeutics, Inc., a privately held biotechnology company advancing a pipeline of antibody therapeutics for mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.Myeloproliferative neoplasms are a group of rare blood cancers where the bone marrow pro ...